Log in to search using one of your social media accounts:

 

Morphosys sees revenue boost as FDA approves psoriasis drug

DUESSELDORF/FRANKFURT (Reuters) - German biotech group Morphosys expects to receive royalties for its psoriasis drug guselkumab for five months this year, its Chief Executive Simon Moroney said, after its licensee received U.S. regulatory approval.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

IL-36γ inhibits differentiation and induces inflammation of keratinocyte via Wnt signaling pathway in psoriasis. Int J Med Sci. 2017;14(10):1002-1007 Authors: Wang W, Yu X, Wu C, Jin H Abstract Psoriasis is a common inflammatory skin disease characterized by abnormal keratinocyte inflammation and differentiation that has a major impact on patients' quality of life. IL-36γ, a member of IL-36 cytokine family, is highly expressed in psoriasis and plays an important role in inflammation response and differentiation. However, the function of IL-36γ in differentiation and inflammation of ke...
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research
Abstract: Prolonged survival of lesional T cells plays a central role in the pathogenesis of T-cell-mediated dermatoses. We have recently shown that the ubiquitin ligase c-CBL is highly expressed in cutaneous T-cell lymphoma (CTCL) and that its knockdown increases activation-induced cell death, a key pathway for T-cell apoptosis. Here, we extend our work on c-CBL expression in malignant T cells to their nonneoplastic counterparts in benign inflammatory dermatoses. Immunohistochemical staining with anti-c-CBL antibody was performed on lesional biopsies from a total of 65 patients with atopic dermatitis, allergic contact der...
Source: The American Journal of Dermatopathology - Category: Pathology Tags: Original Study Source Type: research
CONCLUSION: The present work has confirmed the close relationship between vitiligo and psoriasis. PMID: 28919796 [PubMed]
Source: Clinical, Cosmetic and Investigational Dermatology - Category: Dermatology Tags: Clin Cosmet Investig Dermatol Source Type: research
Publication date: Available online 19 September 2017 Source:Actas Dermo-Sifiliográficas (English Edition) Author(s): C. Bonanad, E. González-Parra, R. Rivera, J.M. Carrascosa, E. Daudén, A. Olveira, R. Botella-Estrada In recent years the concept of psoriasis as a systemic disease has gained acceptance due to its association with numerous comorbid conditions, particularly atherosclerosis and cardiovascular disease. Several studies have shown that patients with psoriasis, especially younger patients and those with more severe forms of psoriasis or with psoriatic arthritis, have a higher prevalence of ri...
Source: Actas Dermo-Sifiliograficas - Category: Dermatology Source Type: research
Innate immune processes are central in the development of the chronic inflammatory skin disease psoriasis. Studying stimulation of keratinocytes, monocytes and dendritic cells by type I interferons or ligation of toll-like receptors TLR1/2, TLR2/6 or TLR7, but not TLR7/8, resulted in enhanced surface expression and secretion of the chemokine CXCL16. The corresponding receptor CXCR6 was expressed on neutrophils whose recruitment into skin is important especially in early psoriatic disease. Using the recently developed technique real-time deformability cytometry demonstrated that CXCL16 and IL-8 decreased the stiffness and e...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Original Article Source Type: research
In this report, one subject took increasing daily doses of vitamin D3 for 6 years starting in April 2009: 6500 IU for 6 months; increasing to 10,000 IU for 13 months; 20,000 IU for 24 months; 40,000 IU for 12 months; 50,000 IU for 10 months, and 60,000 IU since October 2014. 25OHD blood levels were 28, 81, 204, 216, 225, 166, and 218ng/ml. Subject 2 began 10,000 IU in Nov 2011, increased to 20,000 IU in Feb 2014, 25,000 IU in June 2014, and 30,000 IU in Oct 2014, and then decreased to 20,000 IU in June 2015. 25OHD blood levels were 96.6, 161.1 and 106.9ng/ml. He reported marked clinical improvement in his asthma. Subject 3...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
Janssen Research&Development has reported new positive two-year results from the open-label extension of the Phase III VOYAGE 1 trial of Tremfya (Guselkumab) to treat moderate-to-severe plaque psoriasis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
This study aimed to investigate the effect of black seed oil on imiquimod (IMQ) induced psoriasis‐like skin lesions. To this end, 30 male albino rats were divided into three groups: group I, control group; group II, psoriasis‐induced group receiving daily topical applications of IMQ cream (5%) on the shaved back skin for 10 consecutive days; and group III, black seed oil group receiving a daily topical dose of black seed oil 5 mg/kg body weight for 10 days after induction of psoriasis. Animals of all groups were sacrificed and specimens obtained from the skin of the central part of the back were processed for histologi...
Source: The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology - Category: Molecular Biology Authors: Tags: Full Length Article Source Type: research
For those with chronic plaque psoriasis, responses to tildrakizumab, an experimental interleukin-23 inhibitor, were upheld in two long-term extension studies, and FDA approval could be in the offing.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Source Type: news
Source: eMedicineHealth.com - Category: General Medicine Source Type: news
More News: Biotechnology | Germany Health | Health | Psoriasis